Tech Company Financing Transactions
VitriVax Funding Round
F-Prime Capital, private investors and RA Capital Management joined a $87 million Series C capital raise for VitriVax. The financing round closed on 11/18/2026.
Transaction Overview
Company Name
Announced On
11/18/2026
Transaction Type
Venture Equity
Amount
$87,000,000
Round
Series C
Investors
Proceeds Purpose
VitriVax will use the Series C proceeds to advance clinical development of its Lyme disease vaccine candidate and scale its proprietary thermostable vaccine formulation platform in collaboration with global health and defense partners.
Company Information
Company Status
Private & Independent
Industry
Healthcare IT
Mailing Address
3415 Colorado Ave.
Boulder, CO 80303
USA
Boulder, CO 80303
USA
Phone
Undisclosed
Website
Email Address
Overview
VitriVax is a formulation technology company engineering innovative solutions to maximize global accessibility and utility of human and animal vaccines -- vaccines that save lives and protect our world from preventable disease.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 11/18/2026: Pedestal AI venture capital transaction
Next: 11/18/2026: Codex Financial venture capital transaction
Share this article
Where The Data Comes From
We report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs








